MCL1 and breast carcinoma: Furthermore, we validated that treatment with GA led to a significant reduction in TRX and MCL1 expressions in 4T1 breast cancer cells, resulting in highly efficient killing effect (IC50 = 2.20 μg mL−1) against 4T1 cells (Figure S8A,B, Supporting Information).